Use of 2,6-diaminopurine as a potent suppressor of UGA premature stop codons in cystic fibrosis

Abstract excerpt

Nonsense mutations are responsible for around 10% of cases of genetic diseases, including cystic fibrosis. 2,6-diaminopurine (DAP) has recently been shown to promote efficient readthrough of UGA premature stop codons. In this study, we show that DAP can correct a nonsense mutation in the Cftr gene in vivo in a new CF mouse model, in utero, and through breastfeeding, thanks, notably, to adequate pharmacokinetic...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Advanced biosensing and bioanalysis techniques
• Share to Cystic Fibrosis Research Advances
• Share to Respiratory viral infections research